{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:09:17Z","timestamp":1790356157845,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1124\/dmd.111.040212","type":"journal-article","created":{"date-parts":[[2011,8,25]],"date-time":"2011-08-25T02:35:25Z","timestamp":1314239725000},"page":"2182-2190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C"],"prefix":"10.1016","volume":"39","author":[{"given":"Sarah J.","family":"Schrieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy L.","family":"Hawke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdus S.","family":"Wahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Belle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezam H.","family":"Afdhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor J.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Doo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael. W.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.040212_bib1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/ptr.3207","article-title":"Milk thistle in liver diseases: past, present, future","volume":"24","author":"Abenavoli","year":"2010","journal-title":"Phytother Res"},{"key":"10.1124\/dmd.111.040212_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2005.05.051","article-title":"MRP2 and 3 in health and disease","volume":"234","author":"Borst","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1124\/dmd.111.040212_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1572-0241.2004.30159.x","article-title":"Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis","volume":"99","author":"Chalasani","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.111.040212_bib4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1067\/mcp.2003.25","article-title":"Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites","volume":"73","author":"Chalon","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.040212_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1023\/B:PHAM.0000026420.79421.8f","article-title":"The complexities of hepatic drug transport: current knowledge and emerging concepts","volume":"21","author":"Chandra","year":"2004","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.111.040212_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1021\/mp700114j","article-title":"Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity","volume":"5","author":"Cheng","year":"2008","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.111.040212_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/dmd.30.2.129","article-title":"UDP glucuronosyltransferase mRNA levels in human liver disease","volume":"30","author":"Congiu","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1440-1746.2009.05800.x","article-title":"Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease","volume":"24","author":"Congiu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.111.040212_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.111.040212_bib10","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1572-0241.1998.00139.x","article-title":"Milk thistle (Silybum marianum) for the therapy of liver disease","volume":"93","author":"Flora","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.111.040212_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2036.2010.04503.x","article-title":"Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial","volume":"33","author":"Freedman","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.111.040212_bib13","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hep.20683","article-title":"Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism","volume":"41","author":"Galli","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/dmd.111.040212_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jhep.2005.05.031","article-title":"Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat","volume":"43","author":"Geier","year":"2005","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.111.040212_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/09553009214551411","article-title":"Substituent effects in the free radical reactions of silybin: radiation-induced oxidation of the flavonoid at neutral pH","volume":"61","author":"Gy\u00f6rgy","year":"1992","journal-title":"Int J Radiat Biol"},{"key":"10.1124\/dmd.111.040212_bib16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0091270009347475","article-title":"Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C","volume":"50","author":"Hawke","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.111.040212_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0168-8278(02)00060-0","article-title":"Oxidative stress in chronic hepatitis C: not just a feature of late stage disease","volume":"36","author":"Jain","year":"2002","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.111.040212_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/00498254.2011.573017","article-title":"Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases","volume":"41","author":"Jan\u010dov\u00e1","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.111.040212_bib19","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1039\/b300099k","article-title":"Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum)","volume":"1","author":"Kim","year":"2003","journal-title":"Org Biomol Chem"},{"key":"10.1124\/dmd.111.040212_bib20","first-page":"57","article-title":"Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis","volume":"34","author":"Koruk","year":"2004","journal-title":"Ann Clin Lab Sci"},{"key":"10.1124\/dmd.111.040212_bib21","first-page":"990","article-title":"Phase I\/II clinical trial to explore silymarin in chronic liver diseases","volume":"131","author":"Lang","year":"2006","journal-title":"Gastroenterol Hepatol News"},{"key":"10.1124\/dmd.111.040212_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.111.040212_bib23","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.107.015107","article-title":"Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease","volume":"35","author":"Lickteig","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib24","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2165\/00003495-200565170-00003","article-title":"Pathophysiological basis for antioxidant therapy in chronic liver disease","volume":"65","author":"Medina","year":"2005","journal-title":"Drugs"},{"key":"10.1124\/dmd.111.040212_bib25","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1124\/dmd.108.021790","article-title":"Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)","volume":"36","author":"Miranda","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2133\/dmpk.25.190","article-title":"Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters","volume":"25","author":"Ogasawara","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.111.040212_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/dmd.105.007435","article-title":"Expression of UDP-glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney","volume":"34","author":"Richardson","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.111.040212_bib29","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1124\/dmd.107.019604","article-title":"The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3\/7 activity","volume":"36","author":"Schrieber","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jnutbio.2008.07.005","article-title":"Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease","volume":"20","author":"Sookoian","year":"2009","journal-title":"J Nutr Biochem"},{"key":"10.1124\/dmd.111.040212_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/dmd.32.6.587","article-title":"Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases","volume":"32","author":"Sridar","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib32","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1111\/j.1572-0241.2002.05993.x","article-title":"Use of complementary and alternative medicine in patients with liver disease","volume":"97","author":"Strader","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.111.040212_bib33","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1172\/JCI42168","article-title":"Organic anion transporting polypeptide 1a\/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs","volume":"120","author":"van de Steeg","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.111.040212_bib34","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.20784","article-title":"CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice","volume":"42","author":"Wagner","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/dmd.111.040212_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/dmd.107.017566","article-title":"Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract","volume":"36","author":"Wen","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.040212_bib36","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1111\/j.1742-4658.2005.04888.x","article-title":"Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5)","volume":"272","author":"Wu","year":"2005","journal-title":"FEBS J"},{"key":"10.1124\/dmd.111.040212_bib37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2005.07.022","article-title":"Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides","volume":"44","author":"Zelcer","year":"2006","journal-title":"J Hepatol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624225423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624225423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.040212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:02:58Z","timestamp":1739908978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624225423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0090955624225423"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.040212","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.040212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}